CM
DYN icon

Caption Management’s Dyne Therapeutics DYN Stock Holding History

Caption Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100,000
Closed -$1.26M – 1696
2025
Q3 		$1.26M Buy
+100,000
New +$1.14M 0.01% 1028
2024
Q1 		– Sell
-400,200
Closed -$5.32M – 1325
2023
Q4 		$5.32M Buy
+400,200
New +$3.91M 0.07% 309

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Caption Management's DYN Position: Q2 2026 in Review

Caption Management held its Dyne Therapeutics (DYN) position steady in Q2 2026 at 7,894 shares worth $175K. The position accounts for ﹤0.01% of the portfolio, ranked #1479.

Caption Management first reported a position in DYN in Q4 2023 and has held it in 4 quarters since. The position peaked at $2.49M in Q4 2023. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Caption Management held 7,894 shares of Dyne Therapeutics worth $175K as of Q2 2026.
  • Caption Management left its Dyne Therapeutics share count unchanged in Q2 2026.
  • Dyne Therapeutics made up ﹤0.01% of Caption Management's portfolio in Q2 2026, its #1479 holding.
  • Caption Management first reported a position in Dyne Therapeutics in Q4 2023 and has held it in 4 quarters since.
  • Caption Management's Dyne Therapeutics position peaked at $2.49M in Q4 2023.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.